Mark N. Stein
YOU?
Author Swipe
View article: Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors
Association between medication burden and acute care use in older metastatic prostate cancer patients on androgen receptor signaling inhibitors Open
Background Management of metastatic prostate cancer often requires combining androgen deprivation therapy (ADT) with novel androgen receptor signaling inhibitors (ARSIs). Although these agents improve survival, older patients may face acut…
View article: Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma 3574
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma 3574 Open
Description There is a critical need to understand the mechanisms of response and resistance to PD-1 blockade in advanced renal cell carcinoma (RCC). Using scRNA-seq, we previously found increased tissue-resident ZNF683+ SLAMF7+ CD8+ exhau…
View article: 38Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma
38Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma Open
Background Despite the success of immune checkpoint inhibitors (ICI) for the treatment of renal cell carcinoma (RCC), many patients do not receive durable clinical benefit. Therefore, an understanding of resistance to ICIs is critical for …
View article: 4CD163+ Tumor-Associated macrophages and clinical outcomes to First-Line nivolumab therapy in patients with metastatic clear cel renal cell carcinoma: insights from the HCRN GU16-260 trial
4CD163+ Tumor-Associated macrophages and clinical outcomes to First-Line nivolumab therapy in patients with metastatic clear cel renal cell carcinoma: insights from the HCRN GU16-260 trial Open
Background Tumor-associated macrophage (TAM) infiltration has been shown to modulate response to immune checkpoint inhibitors in various cancers, but its role in metastatic clear cell renal cell carcinoma (mccRCC) remains unclear. Here, we…
View article: 18EXACT: a randomized phase II trial of XL092 (zanzalintinib) in combination with immunotherapy in patients who progress on adjuvant therapy in clear cell RCC [NCT06863311]
18EXACT: a randomized phase II trial of XL092 (zanzalintinib) in combination with immunotherapy in patients who progress on adjuvant therapy in clear cell RCC [NCT06863311] Open
Background The randomized phase III KEYNOTE-564 trial demonstrated that adjuvant pembrolizumab improves disease-free survival and overall survival compared to placebo in patients with clear cell renal cell carcinoma (ccRCC) at intermediate…
View article: Novel Strategies and Therapeutic Advances for Bladder Cancer
Novel Strategies and Therapeutic Advances for Bladder Cancer Open
Background/Objectives: To summarize the relevant trials relating to novel strategies and therapeutic advances in the treatment of bladder cancer. Methods: A comprehensive review of the literature and recent/ongoing clinical trials was cond…
View article: Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study Open
PURPOSE We report phase I trial results for pasritamig, a first-in-class, T-cell–engaging bispecific antibody targeting human kallikrein 2 (KLK2) expressed on the surface of prostate cancer (PC) cells. METHODS Participants had metastatic c…
View article: Table S10 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Table S10 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Differential gene expression analysis, including top 1,000 differentially expressed genes for each cluster (compared with all other clusters) for graph-based clustering of nonimmune cells related to, related to Figure 4. Positive log fold-…
View article: Data from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Data from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Immune checkpoint inhibitors targeting the PD-1 pathway have transformed treatment of advanced renal cell carcinoma (RCC), but mechanisms underlying the therapeutic response remain largely unknown. In this study, we perform transcriptomic …
View article: Table S7 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Table S7 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Immune deconvolution (CIBERSORTx) of bulk transcriptomic data, related to Figure 2.
View article: Table S15 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Table S15 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
T cell cytokine secretion data, related to Figure 5.
View article: Table S12 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Table S12 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Differential gene expression analysis, including top 1,000 differentially expressed genes for each cluster (compared with all other clusters) for graph-based clustering of myeloid cells, related to Figure 4. Positive log fold-change (per c…
View article: Figure S1 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Figure S1 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Overview of translational analysis of the HCRN GU16-260 trial, continued from Fig 1.
View article: Figure S13 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Figure S13 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Spatial transcriptomics of TLS and ZNF683+ SLAMF7+ exhausted CD8+ T cells.
View article: Figure S9 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Figure S9 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Functional validation of SLAMF7 activation on T cell functions and flow cytometry gating strategies.
View article: Table S4 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Table S4 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Somatic mutations (MAF file) and significantly recurrent mutations in the HCRN GU16-260 Cohort (Mutig2CV output), related to Figure 1.
View article: Table S13 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Table S13 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Differential gene expression analysis, including top 1,000 differentially expressed genes for each cluster (compared with all other clusters) for graph-based clustering of T cells, related to Figure 5. Positive log fold-change (per cluster…
View article: Figure S12 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Figure S12 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
ZNF683+ SLAMF7+ Exhausted CD8+ T cell and TLS GES integration.
View article: Table S9 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Table S9 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Signatures used for TLS and Teff analysis, related to Figures 2 and 3.
View article: Figure S6 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Figure S6 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
T cell populations identified through scRNA-seq.
View article: Table S16 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Table S16 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
T cell proliferation and exhaustion marker data, related to Figure S9.
View article: Table S8 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Table S8 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Gene set enrichment analysis of differentially expressed genes in patients with complete or partial response using ontology gene sets from MSigDB, related to Figure 2.
View article: Figure S3 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Figure S3 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Association of known T effector signatures and clinical outcomes.
View article: Table S17 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Table S17 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Spearman correlation coefficients, related to generation of ZNF683+ SLAMF7+ CD8+ Exhausted T cell gene expression signature, related to Figure 6.
View article: Figure S11 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Figure S11 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
ZNF683+ SLAMF7+ Exhausted CD8+ T cell GES validation in external clinical cohorts.
View article: Figure S2 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Figure S2 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Analysis of tertiary lymphoid structure enrichment in responders, continued from Fig 2.
View article: Figure S5 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Figure S5 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Non-immune and myeloid populations identified through scRNA-seq.
View article: Table S6 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Table S6 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
Differential gene expression analysis based on bulk RNA-seq, including differentially expressed genes for patients with complete or partial response compared to patients with progressive disease, related to Figure 2. Positive log fold-chan…
View article: Figure S8 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Figure S8 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma Open
TCR specificity in advanced renal cell carcinoma.